Solutions for immune target discovery and design
myNEO is your go-to partner for target discovery and prioritization, for drug product optimization, and for large-scale data analysis support across the different stages of drug development. Our portfolio combines ImmunoEngine antigen discovery with dedicated technologies across therapeutic modalities and disease areas. Each solution can be used independently or combined into an integrated end-to-end workflow.
Accelerate your biologics pipeline
Our technology suite provides comprehensive computational support for antibody, bispecific, ADC, and cell therapy development - from surface target discovery and ADA risk prediction to large-scale data analysis. Explore our asset library for available targets.
mySURFACESurface target discoveryTransmembrane targets and target pairsView product →
myADAAnti-drug antibody risk predictionNext-generation in-silico ADA risk predictionView product →
mySELFAutoimmune disease target discoveryImmunogenic and tolerogenic self-antigen predictionView product →
myINSIGHTSLarge-scale data analysisActionable insights from immuno-genomic dataView product →End-to-end vaccine & T-cell design intelligence
Our technology suite spans the full development lifecycle - from neoantigen discovery and epitope selection to construct design, codon optimization, and clinical data analytics. Relevant discovery and screening workflows use our proprietary neoMS and neoIM algorithms, while dedicated technologies support downstream design and analysis.
myNEOPersonalized neoantigen target discoveryImmunoEngine for personalized immunotherapiesView product →
mySHAREDShared MHC-bound target discoveryCohort-level shared antigen discoveryView product →
myPATHOGENInfectious disease target discoveryAI-guided pathogen antigen selectionView product →mySELFAutoimmune disease target discoveryImmunogenic and tolerogenic self-antigen predictionView product →
myEPITOPEImmunogenicity screeningHigh-precision immunogenicity predictionView product →
myCONSTRUCTAmino acid construct optimizationRational multi-epitope construct designView product →
myRNACodon optimizationNext-generation codon optimization engineView product →myINSIGHTSLarge-scale data analysisActionable insights from immuno-genomic dataView product →Tailored to your project
We offer customized solutions tailored to the needs of our clients and partners. Meet the team behind our innovations.
We have a highly trained team of data scientists with specializations in immunology and genomics, able to manage diverse projects tackling complex biological, clinical, and translational questions. In addition, we have extensive expertise in building customized web-based platforms to ease visualization and interpretation of complex datasets across company departments, clinical studies, or large research projects.
Methods behind the solutions
We publish peer-reviewed immunotherapy and antigen-discovery scientific papers, dedicated technology papers covering myADA, myEPITOPE, myCONSTRUCT, and mySELF, and whitepapers that go deeper into specific target classes and open questions in the field.
What does myNEO offer biologics developers?
For antibody, bispecific, antibody-drug conjugate, and cell therapy programs, myNEO offers surface-target discovery with mySURFACE, anti-drug antibody risk prediction with myADA, self-antigen and tolerance analysis with mySELF, and large-scale translational data analysis with myINSIGHTS.
What does myNEO offer cancer vaccine and T-cell therapy developers?
myNEO supports personalized neoantigen discovery, shared MHC-bound antigen discovery, infectious disease antigen discovery, immunogenicity screening, multi-epitope construct design, mRNA codon optimization, and translational data analysis.
How do customers access myNEO's platforms?
myNEO delivers its live solutions as hosted web applications. myADA (opens in a new tab), mySURFACE (opens in a new tab), and neoHUB (opens in a new tab) are available online. Access is tenant-based so each customer's data remains isolated, with sign-in through Amazon Cognito and multi-factor authentication.
Can I request a demo of a myNEO platform?
Yes. Demonstrations are available for the live myADA, mySURFACE, and neoHUB platforms and can be requested from the relevant product page.
In which countries does myNEO provide its platforms?
There are no geographic restrictions on platform access. The platforms are hosted on AWS and delivered over the web, enabling myNEO to work with customers worldwide. Project-specific data-handling arrangements are agreed contractually.
Does myNEO take on customized computational projects?
Yes. myNEO builds customized computational workflows for biological, clinical, and translational questions. It also develops web-based environments that help teams explore and interpret complex datasets across studies, departments, and research programs.
Can myNEO handle both construct design and codon optimization?
Yes. myCONSTRUCT optimizes epitope order and spacer choice at the amino-acid level to avoid immunogenic junctions. myRNA optimizes the encoding nucleotide sequence for structural stability, codon usage, modified nucleotides, and project-specific constraints. The technologies are often combined but are also available separately.
Talk to our team
Looking for a dedicated solution, a customized project, or a partnership? Our team can help.